KLOW peptide supplies four compounds in a single lyophilized vial totalling 80 mg: GHK-Cu, BPC-157, TB-500, and KPV. It is the broadest blend in this catalogue, assembled around tissue repair and inflammatory research contexts.
The four components
Each acts through a different characterized mechanism, which is the rationale for combining them rather than selecting one.
GHK-Cu—a tripeptide-copper complex (Gly-His-Lys·Cu²⁺, ≈403 g/mol). Studied in copper-dependent modulation of extracellular matrix and tissue-remodeling gene expression, including collagen synthesis and metalloproteinase regulation. CAS 49557-75-7.
BPC-157—a fifteen-residue sequence (GEPPPGKPADDAGLV, ≈1419.5 g/mol) examined through nitric oxide pathway activity and VEGFR2 growth-factor signalling. CAS 137525-51-0.
TB-500—a thymosin beta-4 analogue (≈4963.4 g/mol) whose characterized mechanism is G-actin sequestration, regulating the monomer pool available for filament assembly. CAS 77591-33-4.
KPV—a tripeptide (Lys-Pro-Val, ≈342.4 g/mol) corresponding to the C-terminal fragment of alpha-MSH, studied for melanocortin MC1R anti-inflammatory signalling without the pigmentation activity of the parent hormone. CAS 67727-97-3.
Research context
Matrix remodeling, vascular signalling, cytoskeletal dynamics, and inflammatory modulation are four distinct processes, and the case for a four-component preparation rests on that separation.
It is worth stating the limitation plainly: the more components in a blend, the harder attribution becomes. A four-way preparation is suited to work where a combined effect is the endpoint, not to studies isolating a mechanism. Researchers characterizing any single pathway should use the individual compounds, all of which are available separately. Full technical detail on each is in the GHK-Cu research guide, the BPC-157 research guide, and the TB-500 research guide. For additional scientific background, see the published literature on these peptides.
Specification
KLOW peptide is supplied as a lyophilized powder, 80 mg total, soluble in water or bacteriostatic water. 99%+ purity verified by HPLC and LC-MS. As a blended preparation, no single molecular weight applies—individual figures are listed above.
Handling
Reconstitute with bacteriostatic or sterile water, introducing the diluent against the vial wall and swirling gently rather than shaking.
Because this preparation contains a copper complex, avoid chelating agents such as EDTA in buffer preparations—these will strip the copper from the GHK-Cu component.
Store lyophilized at −20°C protected from light; refrigerate at 2–8°C once reconstituted.
Ships with a batch-specific Certificate of Analysis. Cross-check the batch ID printed on your vial against the CoA before use—see the guide to reading a CoA if you are unfamiliar with the format.
Frequently asked questions about Klow
What is in Klow?
Four compounds totalling 80 mg: GHK-Cu, BPC-157, TB-500, and KPV. Each has a distinct, characterized mechanism—copper-dependent matrix gene expression, nitric oxide and VEGFR2 signalling, G-actin sequestration, and melanocortin MC1R anti-inflammatory activity, respectively. Individual CAS numbers and molecular weights are listed above, since no single figure applies to a blend.
Is a four-component blend appropriate for my study?
Only if a combined effect is the endpoint. This is worth being blunt about: with four compounds acting through four pathways, no observation can be attributed to any one of them. If you are characterizing a mechanism, testing a hypothesis about a specific pathway, or generating data you intend to publish, use the individual compounds—all four are available separately. The blend suits applied work where the preparation as a whole is the subject.
How does Klow differ from Glow?
KPV. Glow contains GHK-Cu, BPC-157, and TB-500—matrix, vascular, and cytoskeletal mechanisms. Klow adds KPV, bringing melanocortin anti-inflammatory signalling as a fourth arm. Where inflammatory modulation is part of the research context, Klow covers it; where it is not, Glow is the narrower preparation.
Does the copper complicate anything?
It constrains buffer choice. The GHK-Cu component means chelating agents such as EDTA will strip the copper and change what you are working with. Screen buffer components before preparing solutions. This applies to any preparation containing GHK-Cu, including Glow and the GHK-Cu + KPV blend.
Research use only. Not for human or veterinary use, not for use in diagnostic procedures, and not evaluated by the U.S. Food and Drug Administration.
